

# **How effective is chelation? contrasts in iron and digoxin poisoning**

**Nick Bateman  
Edinburgh**

# Chelation

- **Chemical chelating agents**  
chemical that bind metal ions and other toxic groups  
e.g. desferrioxamine for iron,  
cobalt edetate for cyanide
- **Antibodies**  
directed against a specific molecule, or against venoms (often in a more complex mixture)  
e.g. Fab antibodies for digoxin  
viper antivenin

# Basic principles: 1

- The toxin is active in and/or mostly dwelling within the blood compartment
- The toxin is bound to a non toxic molecule, and made inactive
- This binding generally is based on mass action  
1 molecule of toxin is neutralised by 1 or more molecules of chelating agent in a fixed proportion
- Thus generally for efficacy  
moles of chelating agent  $\sim$  moles of toxin

## **Basic principles: 2**

- **Ideally need to know the quantity of toxin to calculate the quantity of antidote needed and administer to neutralise**

**BUT**

- **In practice toxin quantity may not be clear**

**So biomarkers of toxin effect may assist dosing decisions**

# Case example

**A 17 year old female ingests her mother's cardiac medication after a domestic argument about her unplanned pregnancy.**

**Ingestion of spironolactone, digoxin and furosemide.  
Patient presents to hospital 5 hours later, complaining of nausea.**

**15 weeks pregnant, has vomited in the ambulance  
normal observations with a pulse rate of 75 /m and normal blood pressure.**

**ECG shows sinus rhythm and no obvious abnormality.**

**An urgent set of bloods are sent and these show  
normal electrolytes,  
serum digoxin of 7 ng/ml (normal therapeutic 1.5-2 ng/ml).**

# Question

- **Would you give Dig Fab??**
- **If so – how much??**

# Case example

A 21 year old female ingests her mother's cardiac medication after a domestic argument about her unplanned pregnancy.

Ingestion of spironolactone, digoxin and furosemide.  
Patient presents to hospital 5 hours later, complaining of nausea.

15 weeks pregnant, has vomited in the ambulance  
normal observations with a **pulse rate of 75 /m and normal blood pressure.**

**ECG shows sinus rhythm and no obvious abnormality.**

An urgent set of bloods are sent and these show  
**normal electrolytes,**  
serum digoxin of 7 ng/ml (normal therapeutic 1.5 – 2 ng/ml).

# **Clinical presentations of digoxin toxicity**

- **toxicity during chronic therapy**
  - **excessive loading dose**
  - **single excess ingestion with heart disease**
  - **single excess ingestion without heart disease**
- 
- **accidental ingestion in a child**


# **Clinical features of digoxin toxicity**

- **GI: nausea, vomiting and diarrhoea**
- **METABOLIC: hyperkalaemia (Na/K ATPase blockade)**
- **CARDIAC: bradycardia and heart block, ventricular arrhythmias**
- **CNS: psychosis and seizures**

# Efficacy

Time course of :  
 total serum digoxin (○ — ○)  
 Free serum digoxin (● — ●)  
 Fab fragments (△ — △)  
 Serum potassium (■ — ■)  
 After iv administration of DA  
 in a 39-year-old man  
 with severe digoxin poisoning.

*Smith TW et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N E J Med 1976;294:797-800.*



# **Requirements for effective use**

**Understanding of toxicokinetics of toxin and kinetics of antidote**


**Dose calculation of antidote dose to neutralise toxin**

**Safety of antidote**

## **Digoxin antibodies.**

### **Binding capacity of Fab fragments**

- **Digibind<sup>R</sup> : 40 mg → 0.62 mg digoxin**
- **Digifab<sup>R</sup> : 40 mg → 0.62 mg digoxin**
- **Digidot<sup>R</sup> : 80 mg → 1 mg digoxin**



**equimolar dose = Digibind<sup>R</sup> and Digifab<sup>R</sup>**  
**: BL (mg) x 65**

**digidot<sup>R</sup> : BL (mg) x 80**

# **Digoxin antibodies: when ?**

- **life-threatening features**
  - **hyperkalemia**
  - **severe poisoning: HR < 50/mn**
- 
- **patients at risk: elderly, underlying cardiac disease, mixed poisoning (cardiotropic drugs)**

# **Digoxin antibodies. How much ?**

**Optimal dose MAY NOT BE equimolar dose**

**AIM to achieve neutralization of sufficient body-load (BL) of digoxin or digitoxin to stop toxic effect**

**Avoid waste of Fab by too rapid infusion**

# Proposed strategy of digoxin Fab administration: Digibind<sup>R</sup>; Digifab<sup>R</sup>

**0 hr** ASSESSMENT

No Treatment

Monitor

**R -**

**2 hr**

Surveillance

**R -**

**9 hr**

other cause?

Loading dose :

160 mg (4 vials) over 0.25 - 1 h

**R +**

? 160 mg / 7 hours if symptomatic

**R +**

Surveillance

Further doses as clinically indicated

## **Dynamics of the Digoxin-Fab complex**

**Dissociation of digoxin from the antibody or tissue redistribution, may lead to rebound of free digoxin and recurrence of toxic features.**

**Continue cardiac monitoring 24 hours after treatment (and longer in cases of severe renal failure).**

## **Digoxin antibodies: how much ?**

- **pragmatic strategy based on the clinical response**
- **don't use the Fab too quickly**
- ***treat the patient and not the serum level***

# **Pitfalls of body-load calculation**

## **Variations :**

- **the kinetic-dynamic relationship (acute, acute/chronic, chronic poisoning)**
- **age**
- **underlying cardiac disease**
- **electrolyte disturbances ( $K^+$ )**
- **associated cardiotropic drugs**

# Iron content of Tablets

## Iron Content of Salts

| Iron Salt                | Tablet Size | Elemental Iron Content |
|--------------------------|-------------|------------------------|
| Ferrous fumarate         | 200 mg      | 65 mg                  |
| Ferrous gluconate        | 300 mg      | 35 mg                  |
| Ferrous succinate        | 100 mg      | 35 mg                  |
| Ferrous sulphate         | 300 mg      | 60 mg                  |
| Ferrous sulphate (dried) | 200 mg      | 65 mg                  |

# **How does iron cause toxicity??**

- **“Cellular dysfunction and death”**

**“Exact mechanism is unknown”**

**Features in severe cases are metabolic (lactic) acidosis, coma and multi-organ failure: all presumably due to intracellular toxicity**

# **Westlin: Clin Paeds 1966**

**144 no coma or “shock” no deaths**

**28 coma or “shock” 3 deaths**

**46 conc > 5mg/L: 17 coma +/- shock  
29 asymptomatic**

**Difficult to find a pattern as cases not uniformly collected**

Chyka and Butler:  
Am J Emerg Med 1993

**TABLE 2.** Relationship of Serum Iron Concentrations Above and Below 500 µg/dL and the Presence of Various Clinical or Laboratory Variables

| Variable and<br>Serum Iron (µg/dL) | No. of Patients     |                    | Predictive<br>Value<br>Positive | Predictive<br>Value<br>Negative | Odds<br>Ratio | 95% Confidence<br>Interval |        |
|------------------------------------|---------------------|--------------------|---------------------------------|---------------------------------|---------------|----------------------------|--------|
|                                    | Variable<br>Present | Variable<br>Absent |                                 |                                 |               |                            |        |
| Coma*                              |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 1                   | 83                 | 0.67                            | 0.93                            | 27.67         | 4.55                       | 168.38 |
| >500                               | 2                   | 6                  |                                 |                                 |               |                            |        |
| Radiopacities                      |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 24                  | 46                 | 0.17                            | 0.96                            | 4.79          | 0.97                       | 23.70  |
| >500                               | 5                   | 2                  |                                 |                                 |               |                            |        |
| WBC >15,000 mm <sup>3</sup>        |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 15                  | 54                 | 0.21                            | 0.93                            | 3.60          | 0.85                       | 15.19  |
| >500                               | 4                   | 4                  |                                 |                                 |               |                            |        |
| Anion gap >15                      |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 21                  | 41                 | 0.19                            | 0.93                            | 3.25          | 0.74                       | 14.25  |
| >500                               | 5                   | 3                  |                                 |                                 |               |                            |        |
| Glucose >150 µg/dL                 |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 14                  | 45                 | 0.12                            | 0.90                            | 1.29          | 0.22                       | 7.44   |
| >500                               | 2                   | 5                  |                                 |                                 |               |                            |        |
| Vomiting                           |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 56                  | 28                 | 0.08                            | 0.90                            | 0.83          | 0.18                       | 3.77   |
| >500                               | 5                   | 3                  |                                 |                                 |               |                            |        |
| Diarrhea                           |                     |                    |                                 |                                 |               |                            |        |
| ≤500                               | 37                  | 47                 | 0.08                            | 0.90                            | 0.76          | 0.17                       | 3.41   |
| >500                               | 3                   | 5                  |                                 |                                 |               |                            |        |

Abbreviation: WBC, white blood cell count.

\*  $P = .02$ ; all others not significant at  $P < .05$ .

# Chyka and Butler: Pharmacother 1996




Figure 1. Serum iron concentrations after time of ingestion for patients categorized as no symptoms (○), gastrointestinal symptoms (◻), CNS changes (◊), or cardiovascular instability (△).

# Iron poisoning (TOXBASE)

- Ingested dose elemental iron (mg/kg body weight) and features seen

## DOSE INGESTED

- Less than 20 mg/kg Mild features,
- More than 20mg/kg Features likely
- 150 – 300 mg/kg Severe - possibly fatal
- US textbooks suggest >60mg/kg potentially fatal

# Concentrations in Iron poisoning (TOXBASE)

- 3 mg/L (55 micromol/L) mild toxicity
- 3-5 mg/L (55-90 micromol/L) moderate toxicity
- > 5 mg/L (90 micromol/L) potentially severe toxicity

# Iron poisoning


- **PROBLEM**
- **> 5 mg/L (90 micromol/L) marker of “severe toxicity” is often found during acute ingestion phase prior to distribution**
- **Many such patients subsequently have a fall in concentration and seem fine**
- **If you treat these patients they get better anyway,  
? biasing efficacy reports**

# HOW MUCH IRON IS PRESENT?


- **Amount = Concn x VD**
- **What is the correct volume to use for VD?**
- **Plasma, (~ 5L) , or Total Body Water (~ 40L)**
- **WHY IS THIS IMPORTANT??**

# Iron distribution in OD:

## A 1<sup>st</sup> 24 hours. B 24+ hours



# Desferrioxamine



- 
- **Binds iron in molar equivalent amounts**
- **560.7 DFO gm/mol**
- **100 mg binds ~ 8.5 mg Fe**

# Desferrioxamine

Volume of distribution 0.6- 1.3 L/kg

Several metabolites (one ? Toxic)

T<sub>1/2</sub> in Thalassaemia ~3hr

Ferrioxamine VD 0.2 L/kg  
(renal excretion active and passive)

# **How Much Elemental Iron is Toxic??**

## **Iron in a 50kg patient**

### **TOXBASE**

**150 – 300 mg/kg**

**Severe – possibly fatal toxic dose/kg x wt:**

$$150 \times 50 = 7,500 \text{ mg} = >100 \text{ tablets FeSO}_4$$

**US Texts >60mg /kg possibly fatal**

$$60 \times 50 = 3,000 \text{ mg} = 50 \text{ Tablets FeSO}_4$$

# **Desferrioxamine and Iron**

**100 mg of DFO binds ~8.5 mg elemental iron**

**“Maximum dose” of desferrioxamine is 90 mg/kg**

**Thus in a 50 kg patient**

**90mg/kg DFO (4500 mg) binds ~380 mg elemental iron**

**REMEMBER Toxic elemental iron dose is 3,500-7000 mg**

# **Desferrioxamine and Iron**

## **PROBLEM**

**Once DFO given iron levels cannot be easily interpreted**

**Iron levels are not well studied in early phases of OD (often go up then down)**

**What do we need?**

**better assessment of DOSE response to Iron and DFO**

**? A NOMOGRAM**

# DEFERRIOXAMINE TOXICITY

## Is it a real problem??

- Hypotension: Whitten's first studies in 1965 and 66. 800 and 1500 mg DFO over 15 minutes in 3 children. 2 hypotensive, 1 fitted. All survived.
- Pulmonary toxicity: ARDS reported in 4 adults receiving prolonged (days) 15 mg/kg/hr doses (Tenenbein et al 1992) for iron poisoning.  
Also reported in higher dose DFO in thalassaemia
- Ocular toxicity: All in chronic iron overload with "high dose" DFO
- Yersinia and mucormycosis infection: in long term management
- Studies in dogs lead to empiric max rate of 15mg/kg/hr

## **Desferrioxamine and Iron in a 50kg patient**


- **Is it logical binding so little Iron is likely to work?**
- **Shouldn't chelator dose and iron dose be used together ?**
- **Complicated by changes in bioavailability of iron in poisoning**

# Survival After a Severe Iron Poisoning Treated with Intermittent Infusions of Deferoxamine

Clinical Toxicology, 33(1), 61-66 (1995)

Karla Cheney, M.D.\*; Carl Gumbiner, M.D.\*; Blaine Benson, Pharm.D.\*\*; Milton Tenenbein, M.D.\*\*\*

*University of Nebraska Medical Center\*; The Poison Center  
Children's Hospital\*\*, Omaha, Nebraska; The Winnipeg  
Children's Hospital and the University of Manitoba, The Manitoba  
Poison Control Centre, Canada\*\*\**



**Figure 1** A summary of our patient's clinical course.

# **Take-Home messages:- 1**

**Digoxin FAB is effective, but should be reserved for patients who are suffering severe effects of digoxin**

**(eg bradycardia, hyperkalaemia and life-threatening arrhythmias)**

**In most patients full neutralisation is unnecessary, and dose of Fab can be titrated**

## **Take-Home messages:- 2**

**The evidence base for efficacy of chelation of Iron in ACUTE OD is not good**

**Optimum time for delivery BEFORE 1<sup>st</sup> 24 –36 hr  
BUT treatment assessment early is difficult in all  
except very severe cases**

**Doses of desferrioxamine should ideally be  
better calculated to match the body burden  
of the toxin**

# Conclusion

- **Chelating agents are effective in some poisonings**
- **The theory is simple**
- **Digoxin shows a good approach**
- **Iron shows the problems of metal chelation**
- **There are few (if any) examples where there is uncontroversial evidence of a chelator's clinical efficacy in metal poisoning**

# **Thankyou**

**[drnickbateman@gmail.com](mailto:drnickbateman@gmail.com)**